Annual Review of Pharmacology and Toxicology 1998 - 2002: Vol 38-42 Index & Table of Contents

39 Pages·8.5 MB·English

SUBJECT INDEX
A xenobiotics for, 6-7 inhibition by, 245
A-kinase anchoring protein Activation of MAP kinase signaling complexes, 244
(AKAP) cascades by integrins Alb-PXR
regulation of PKA by, direct, 289-91 See Wild-type human PXR
236-37 Active site signature motif, Allergenicity assessment,
A-kinase anchoring protein 210 109-10
(AKAP) mediated signal ADAPT II software, 120 Allergens
transduction, 235-57 Adenine nucleotide sequence homology to
coordination of multivalent translocator (ANT), 266 known, 104—5
signaling complexes by Adenomatous polyposis coli Allergy & Immunology
A-kinase anchoring (APC), 61, 299 Institute, 102
protein (AKAP), 238 Adenosine triphosphate Altered DNA methylation,
cyclic AMP-dependent (ATP), 325-28 501-25
protein kinase, 236 structural studies of, carcinogenesis as a
evolution of A-kinase 327-28 multistage, multistep
anchoring proteins Adhesion receptor families, process, 502-3
(AKAPs), 237-38 284-88 cell proliferation and
muscle A-kinase anchoring and associated cytoskeletal carcinogenesis, 512—14
proteins (mAKAPs), components, 285 DNA methylation and
238-48 cadherins, 286 carcinogenesis, 505-9
regulation of PKA by Ig CAMs superfamily, 287 importance of epigenetic
A-kinase anchoring integrins, 284-86 mechanisms, 503-5
protein (AKAP), 236-37 selectins, 287-88 and imprinting, 510-12
A1298C polymorphism, 190 Adverse Drug Reaction interrelationships between
Abbott Laboratories, 388 Terminology, 122 mutagenesis, genome
Absorption Aequorea Victoria, 411 stability, 509-10
of tea catechins, 29-30 Affinity labeling, 438-39 as a secondary mechanism
(2-Acetoxypheny]) Agronomic benefits underlying
heptynylsulfide (APHS), from genetically modified carcinogenesis, 515-18
63 foods, 100 significance of secondary
Acids AIF mechanism concept,
See Arachidonic acid; Bile See Apoptic-inducing 501-2
acids; Cellular retinoic factor Altered DNA methylation as
acid binding protein; Airway hyperresponsiveness a secondary mechanism
Chenodeoxycholic acid; (AHR), 82, 84-87 underlying
Fatty acids; Lithocholic AKAP 350/450/CG-NAP carcinogenesis, 515-18
acid; Retinoic acid coordinated signaling heritable, aberrant patterns
receptors; complexes, 246-47 of methylation, 517
Taurochenodeoxycholic YOTIAO, 24446 normal patterns of
acid; Valproic acid AKAP220, 242-43 methylation, 517
Activating PXR RII binding enhancing PPI Aminergic G protein
602 SUBJECT INDEX
aminergic GPCR structure Antihyperalgesic vs. proinflammatory
and molecular modeling, analgesic actions of cytokines, 87
450-54 NSAIDs, 554 inhibition of T helper 2
binding site of, 437-67 Antioxidative properties of (Th2) cytokines, 82-87
general indexing method tea polyphenols, 28-29 other approaches to
for residue numbering, AP-1 and related activities cytokine inhibition,
438 inhibition of, 43 92-93
methods to identify binding APC strategies for inhibiting
site residues, 438-50 See Adenomatous cytokines, 81-83
second extracellular loop, polyposis coli ATP
454-57 APHS See Adenosine
Aminergic GPCR structure See (2-Acetoxypheny]) triphosphate
and molecular modeling, heptynylsulfide (APHS) Autographa californica, 263
450-54 Aplysia californica, 143
binding site, 451-52 Apoptic-inducing factor B
receptor activation, 454 (AIF), 266 Backphosphorylation, 242
structural bases of Apoptosis Bacterial ligases
pharmacological inhibition of, 43-44 production of D-ala-D-X
specificity, 452-54 Arabidopsis thaliana, 528 dipeptides by, 389
Amines Arachidonic acid Bactericidal effect of
biogenic, 2 conversion to PGH2, 57 vancomycin on
Amycolatopsis orientalis, 381 Aspergillus, 328 Gram-positive bacteria,
Amy] nitrate, 585 Aspirin, 63 384
Angiogenesis Assessment of allergenicity Baculoviral [AP repeat (BIR)
inhibition of invasiveness of foods produced domains, 261-62
and, 45 through agricultural Basic fibroblast growth factor
Animal models, 107-8 biotechnology, 101-9 (BFGF), 198
Animal studies, 170-71 animal models, 107-8 Bcl-2 family members,
ANT FAO/WHO decision tree 265-68
See Adenine nucleotide approach to, 103 Bcl-2 homology (BH)
translocator level of expression of the domains, 264
Anti-IL-1, 87 novel protein, 109 BEL
Anti-IL-4, 85-86 resistance to pepsin, 107 See Bromoenol lactone
Anti-IL-5, 82-85 sequence homology to Benzo[a]pyrene (BP), 33
Anti-IL-9, 87 known allergens, 104—S Betamethasone, 3
Anti-IL-13, 86-87 source of the novel gene, BFGF
Anti-inflammatory cytokines, 1024 See Basic fibroblast growth
88-90 specific serum screening, factor
IL-10, 88-89 105-6 BH
IL-12, 89-90 targeted serum screening, See Bcl-2 homology
IL-18, 89-90 106-7 domains
interferons, 89 Asthma therapies, 81—98 Bidentate inhibitors, 223
Anti-TNF, 87 anti-inflammatory Bile acids, 2-3
Anticancer activities cytokines, 88-90 binding and activating
mechanisms of, 42-46 chemokine inhibitors, 82, PXR, 12
studies in cell lines, 42-45 90-92 “Bin size,” 128
Antifungal drugs, 4 inhibition of Binding mode, 476-88
SUBJECT INDEX 603
of chemokine receptors, Bioavailability and Biomedical informatics and
479-82 pharmacokinetics, 29-32 pharmacogenomics
of chemokines, 476-88 absorption and approaches to
of hymenialdisine, 346 biotransformation of tea pharmacogenomics,
of indirubin monoxime, catechins, 29-30 115-16
331 pharmacokinetics of tea biomedical informatics
of inhibitors, 344 polyphenols, 30-32 defined, 113-14
of purvanalol, 337 Biochemical information challenges for, 113-33
of PXR, with xenobiotics, processing by ERK, comparing genomes to
6-7 152-54 develop
Binding site residues blockade of ERK activation pharmacogenomic
affinity labeling, 438-39 as a synaptic lock, 154 models, 126
effects of mutations on ERK as a biochemical data exchange standards,
receptor isomerization, information storage 122
446-47 mechanism, 154 developing communication
identification of direct ERK as a biochemical standards in
ligand contacts, 447-48 switch, 153 pharmacogenomics,
implicated in ligand ERK as a coincidence 121-22
binding, representative, detector, 153-54 integrating data from
443-45 ERK as a temporal diverse and heterogeneous
mapping the surface of the integrator, 154 databases, 123
binding-site crevice with Biochemistry and physiology managing laboratory
the substituted-cysteine of S-nitrosothiols, information data, 126-27
accessibility method, 585-600 mining published literature
449-50 chemistry, 586-87 for pharmacogenomic
methods to identify, S-nitrosothiols, nitric oxide data, 123-24
438-50 and the blood stream, pharmacogenetics and
second-site revertant 592-95 pharmacogenomics
mutations, 448-49 S-nitrosothiols and signal defined, 115
site-directed mutagenesis, transduction, 590-92 phenotype-to-genotype
439-48 S-nitrosothiols as approaches, 116-17
in the transmembrane modulators of enzyme protecting confidentiality
domain implicated in activity, 589-90 and privacy of clinical
ligand binding, 440-42 stability and biological phenotype data, 127-28
Binding sites, 437-67 chemistry, 587-89 representing the diversity
aminergic GPCR structure Biogenic amines, 2 of pharmacogenomic
and molecular modeling, Biology of the spinal cascade data, 118-20
450-54 induced by tissue injury, understanding structural
on the cytoplasmic domain 554-56 consequences of genetic
of NHE1, 536 circulating factors, 556 variations, 125-26
general indexing method dorsal horn at level of the using expression data to
for residue numbering, primary afferent synapse, assess the phenotypes of
438 555 drug response, 124-25
methods to identify binding neural linkages, 556 Biomedical informatics
site residues, 438-50 Bioluminescence resonance defined, 113-14
second extracellular loop, energy transfer (BRET), BIOML, 118
454-57 411-12 Biotransformation
604 SUBJECT INDEX
of tea catechins, 29-30 Calmodulin, 537 tea and cancer, 41-42
Biphenyls Cambridge Crystallographic inhibition of tumorigenesis
polychlorinated, 4 Database, 119 in animal models, 32-41
BIR Camellia sinensis, 26 mechanisms of anticancer
See Baculoviral IAP repeat cAMP response element activities, 42-46
domains binding protein (CREB) tea chemistry, 26-28
Birth defects regulation of Carcinogenesis secondary
environmentally induced, phosphorylation in the mechanism, 501-25
181-208 hippocampus, 150-51 altered DNA methylation
Bis-aryldifluorophosphonate transcription factor, 148-49 as, 515-18
inhibitors, 222 CAMs carcinogenesis as a
Black tea polyphenols (BTP), See Constitutively active multistage, multistep
32, 39 mutants process, 502-3
Bladder carcinogenesis Canola cell proliferation and
protection against, 40 genetically modified, 100 carcinogenesis, 512-14
Blockades Carcinogenesis DNA methylation, 505-6
of COX isozyme decreased availability of DNA methylation and
expression, 563 methyl groups causing carcinogenesis, 506-9
of ERK activation as a liver tumors in rodents, importance of epigenetic
synaptic lock, 154 508 mechanisms, 503-5
BOP DNA methylation and, imprinting, 510-12
See N-Nitroso-bis 506-9 interrelationships between
(2-oxopropyl)amine hypermethylation, 508-9 mutagenesis, genome
BP hypomethylation, 506-8 stability, and altered DNA
See Benzo[a]pyrene inhibition of, possible methylation, 509-10
Brain-derived neurotrophic mechanisms for, 45-46 significance of secondary
factor (bdnf ), 198-99 maintenance of DNA mechanism concept,
Brazil nuts methylation, 507 501-2
allergenicity of, 109-10 as a multistage, multistep Caspase recruitment domain
Bromoenol lactone (BEL), process, 502-3 (CARD), 261-62
558 possible epigenetic basis Caspases
BTP for initiation of, 504-5 FLICE-inhibitory protein,
See Black tea polyphenols possible inverse 263-64
(BTP) relationship between inhibition of apoptosis at
N-Butyl-N-(4- susceptibility to the level of, 261-64
hydroxybuty])nitrosamine, carcinogenesis and inhibitors of apoptosis
41 capacity of maintaining proteins family members,
Butyrolactone, 328 normal patterns of DNA 261-62
methylation, 509 Catechin gallate, 26, 44
& susceptibility to, 509 CBS
Cadherins, 286 Carcinogenesis inhibition by See Cystathionine
regulating signaling in the tea, 25-54 B-synthase
WNT pathway, 301 antioxidative properties of CCR2 inhibitors, 91
Cadherins/B-catenin tea polyphenols, 28-29 CCR3 inhibitors, 90-91
signaling by, 299-303 bioavailability and CCR4 inhibitors, 92
Caenorhabditis elegans, 237, pharmacokinetics, 29-32 Cdc25 inhibitors, 226-27
259-62, 264, 528 epidemiological studies on structures of
SUBJECT INDEX 605
small-molecule Cdce25 Database, 119, 126 Chemokine receptors, 479-82
inhibitors, 227 Cell survival and apoptosis, small-molecule antagonists
Cdks 540-42 of, 484-88
development of inhibitors, Cellular actions of NHE1, Chemokines, 477-79
328-46 538-43 with known
inhibition by quinazoline cell survival and apoptosis, three-dimensional
compounds, 344 540-42 structures and their
structural studies of, cytoskeletal organization receptors, 473-74
327-28 and migration, 542-43 Chemoprevention of
Celecoxib, 66-67, 69 effect of NHE1 activity on intestinal tumors by
metabolism of, in humans, cell proliferation, 541 aspirin and other
67 proliferation, 539-40 NSAIDs
Celera browser, 118 Cellular mechanisms for the inhibition of
Cell-cell adhesion receptors repression of apoptosis, cyclooxygenases, 67—70
regulation of signaling 259-81 mechanisms for, 67-70
cascades by, 299-305 at the level of caspases, Chenodeoxycholic acid, 12
Cell-cycle regulation 261-64 Chloroeremomycin, 384
modulation of, 44 at the level of the Cholestasis
Cell death program mitochondria, 264-68 potential utility of PXR in
activation of, 272 at the level of the plasma treatment of, 12-13
Cell line studies, 42-45 membrane, 268-72 Cholesterol 7a-hydroxylase
inhibition of apoptosis, Cellular pharmacogenomic (Cyp7al), 11
43-44 data, 119 Ciliary neurotrophic factory
inhibition of invasiveness Cellular retinoic acid binding (cnif), 198
and angiogenesis, 45 protein (CRABP), 195 Circulating factors, 556
inhibition of MAP-kinases, Cellular retinol binding Cisplatin, 33
AP-1, and related protein (CRBP), 194-95 Cleft lip/palate (CL/P),
activities, 43 Central nervous system 191-72
inhibition of NFxB and (CNS) Clinical importance of
related activities, 43 actions of COX inhibitors research, 569-70
interference on receptor in man, 568-69 Clinical interventions,
binding and related COX isozyme inhibition in 171-72
activities, 4445 human pain states, 569 Clinical pharmacogenomic
modulation of cell-cycle and data, 120
regulation, 44 noninflammatory-induced Clostridia, 381
Cell proliferation experimental pain, Clotrimazole, 4
and carcinogenesis, 512-14 568-69 CNS
effect of NHE1 activity on, postmitotic neurons of, See Central nervous system
541 143 Co-immunoprecipitation as a
multiple factors controlling spinal drug delivery, 569 tool to determine homo-
DNA methylation, 514 CHARMM, 450 and heterodimerization,
in multistage Chelators, 587 410-11
carcinogenesis, 504 Chemokine inhibitors, 82, Colon cancer prevention
varied roles alterations in 90-92 COX-2? as target for,
DNA methylation play in CCR2 inhibitors, 91 55-80
carcinogenesis, 513-14 CCR3 inhibitors, 90-91 COX-2 inhibitors in the
Cell Signaling Network CCR4 inhibitors, 92 clinic, 66-67
606 SUBJECT INDEX
COX-independent relating aspirin intake to cyclooxygenase and
mechanisms, 70-71 reduced mortality from peroxidase activities of
COX inhibition, 62—63 colon cancer, 60 COK, 57
development of COX-2 and NSAIDs, 59-60 Coordination of multivalent
inhibitors, 63—66 risk reduction in human signaling complexes by
discovery of COX-2, sporadic colorectal A-kinase anchoring
61-62 carcinoma, 59-60 protein (AKAP), 238
kinetics of COX-2 Combinatorial synthesis of Corn
inhibition, 66 2,6,9-trisubstituted insect-resistant, 99-100
mechanisms for purines, 336 Correlation between effect of
chemoprevention of Communication standards in mutagenesis and PTPs,
intestinal tumors by pharmacogenomics 213-14
aspirin and other drug and compound names, Cortical atrophy, 172-73
NSAIDs, 67—70 121-22 Corticosteroids, 92
metabolism of celecoxib in human gene names and Corticosterone, 6
humans, 67 links to other organisms, COSTART, 122
metabolism of refecoxib in 121 Cotton
humans, 68 side effects, 122 genetically modified, 100
naturally occurring COMPARE analysis, 334, COX-2 as target for colon
salicylates, 56 340 cancer prevention,
nonsteroidal Comparing genomes to 55-80
anti-inflammatory drugs develop COX-2 inhibitors in the
(NSAIDs) and colorectal pharmacogenomic clinic, 66-67
cancer, 59-60 models, 126 COX-independent
nonsteroidal Conditioning mechanisms, 70-71
anti-inflammatory drugs Pavlovian, 137 COX inhibition, 62-63
(NSAIDs) and Confidentiality of clinical development of COX-2
cyclooxygenase, 56-59 phenotype data inhibitors, 63-66
nonsteroidal protecting, 127-28 discovery of COX-2,
anti-inflammatory drugs Congenital anomalies 61-62
(NSAIDs) use and defined, 183-84 kinetics of COX-2
reduction of adenoma size CONSAM software, 120 inhibition, 66
and number in familial Constitutive dimerization mechanisms for
adenomatous polyposis effect of agonist on the chemoprevention of
(FAP), 60-61 dimers detection, 416-18 intestinal tumors by
risks of chronic NSAID vs. ligand-promoted, aspirin and other
therapy for cancer 414-19 NSAIDs, 67-70
prevention, 71-72 Constitutive location of spinal metabolism of celecoxib in
structure of COX COX isozymes, 558-59 humans, 67
inhibitors, 65 Constitutive spinal metabolism of refecoxib in
structure of NSAIDs and localization of PLA2 humans, 68
related compounds, 64 isozymes, 557 naturally occurring
worldwide sales of Constitutively active mutants salicylates, 56
NSAIDs and COX-2 (CAMs), 446 nonsteroidal
inhibitors, 69 Conversion of arachidonic anti-inflammatory drugs
Colorectal cancer acid to PGH2 by (NSAIDs) and colorectal
epidemiological studies combined action of cancer, 59-60
SUBJECT INDEX 607
nonsteroidal element binding protein of PGH?> to
anti-inflammatory drugs CrmA prostaglandins, 58
(NSAIDs) and inhibition of apoptosis by, and NSAIDs, 56-59
cyclooxygenase, 56-59 263--64 Cyclosporin A, 81, 92
nonsteroidal CSAIDS Cydai pomonella
anti-inflammatory drugs See Cytokine synthesis granulovirus (CpGV),
(NSAIDs) use and anti-inflammatory drugs 261
reduction of adenoma size Cubic ternary complex (CTC) CYP expression inducible by
and number in familial! model xenobiotics, 2
adenomatous polyposis of G protein activation, CYP3A subfamily, 2-15
(FAP), 60-61 351-53, 360 evidence that PXR is a key
risks of chronic NSAID Current concepts regarding regulator of induction by
therapy for cancer signaling scaffolds, xenobiotics, 6-11
prevention, 71-72 306-7 expression and catalytic
structure of COX Current Procedural activity, 2-3
inhibitors, 65 Terminology, 120 identification of novel PXR
structure of NSAIDs and Cyclic AMP-dependent target genes, 13
related compounds, 64 protein kinase, 236 induction by structurally
worldwide sales of Cyclin-dependent kinase diverse compounds, 3-4
NSAIDs and COX-2 inhibitors, 325-48 metabolism of endogenous
inhibitors, 69 binding mode of compounds, 3
COX-2 inhibitors hymenialdisine, 346 metabolism of xenobiotics,
in the clinic, 66—67 binding mode of indirubin 2-3
development of, 63-66 monoxime, 331 pregnane X receptor
worldwide sales of, 69 binding mode of inhibitors, (PXR), 5
COX-independent 344 role of PXR in bile acid
mechanisms, 70-71 binding mode of homeostasis, 11-13
COX inhibition purvanalol, 337 transcription regulation by
structural basis of, combinatorial synthesis of pregnane X receptor,
62-63 2,6,9-trisubstituted 1-23
COX isozyme expression purines, 336 X-ray crystal structure of
regulation of, 565-68 discovery and development the PXR LBD, 13-15
COX isozyme inhibition of cdk inhibitors, 328-46 xenobiotic response
in human pain states, 569 hymenialdisine, 345 elements in, 4-5
COX pharmacology, 560 indirubin and analogues, Cyp7al
CpGV 331 See Cholesterol
See Cydai pomonella quinazoline compounds, 7a-hydroxylase
granulovirus 344 Cyp7B1
CPLA2, 556-57 structural studies on cdk2, See Oxysterol
CRABP ATP, and cyclins, 327-28 7a-hydroxylase
See Cellular retinoic acid various compounds, Cyp8B1
binding protein See Oxysterol
CRBP Cyclooxygenase (COX) 12a-hydroxylase
See Cellular retinol binding conversion of arachidonic CYP27
protein acid to PGH>, 57 See Sterol 27-hydroxylase
CREB inhibitors of, 67—70, 554 Cyproterone acetate, 4
See cAMP response metabolic transformations Cystathionine B-synthase
608 SUBJECT INDEX
(CBS), 190 D 2,2’-Dihydroxy-di-n-
Cytochrome P450 D-ala-D-X dipeptides propylnitrosamine,
superfamily (CYPs), 1-2 production by bacterial 41
CYP expression inducible ligases, 389 Dimerization
by xenobiotics, 2 D-cycloserine (DCS), co-immunoprecipitation as
Cytokine inhibitory 171-72 a tool to determine homo-
approaches, 92-93 D-serine, 171 and heterodimerization,
corticosteroids, 92 DAMGO-receptor 410-11
immunomodulators, 92 complexes, 363, 421, constitutive vs.
NF-«B inhibitors, 93 425-26, 428 ligand-promoted, 414-19
p38 mitogen-activated Data exchange standards, 122 emerging concept for G
protein (MAP) kinase DBD protein-coupled receptors
inhibitors, 93 See DNA binding domain ontogeny and function,
phosphodiesterase 4 DCI 409-35
inhibitors, 92 See Dichloroisoproterenol of glycopeptide antibiotics,
Cytokine modulators as novel DCS 385
therapies for asthma, See D-cycloserine Dimers
81-98 Death effector domains bioluminescence resonance
anti-inflammatory (DED), 263 energy transfer, 411-12
cytokines, 88—90 Death inducing signaling detection in living cells,
chemokine inhibitors, 82, complex (DISC), 263 411-14
90-92 Decaffeinated green tea effect of agonist on
inhibition of (DGT), 30-31 detection, 416-18
proinflammatory Decreased availability of fluorescence resonance
cytokines, 87 methyl groups causing energy transfer, 412-14
inhibition of T helper 2 liver tumors in rodents, as signal transducing units,
(Th2) cytokines, 82-87 508 422-27
other approaches to DED Dimethylamiloride (DMA),
cytokine inhibition, 92-93 See Death effector domains 530-31
strategies for inhibiting Delayed Word Recall and (+)-1-(2,5-Dimethoxy-4-
cytokines, 81-83 Verbal Fluency test, 168 iodopheny])-2-
Cytokine synthesis Deltorphin II, 425, 428 aminopropane (DOJ),
anti-inflammatory drugs Deschloroflavopiridol, 329 359
(CSAIDS), 93 Development 7,12-Dimethylbenz[aJanthra-
Cytokines of cdk inhibitors, 328-46 cene (DMBA), 32, 38,
suppression of signaling, of COX-2 inhibitors, 40
86 63-66 Dioxins, 188
See also Proinflammatory Developmental processes, Dipeptides
cytokines; T helper 2 184-87 See D-ala-D-X dipeptides
cytokines Dexamethasone, 3-8 Direct activation of MAP
Cytoskeletal organization and DGT kinase cascades by
migration, 542-43 See Decaffeinated green integrins, 289-91
Cytoskeletal scaffolds tea Direct regulation of NHE1,
in the MAP kinase cascade, Dichloroisoproterenol (DCD), 535-38
309-10 359-61 additional regulatory sites,
signal transduction and, Difluromethylthiophenols, 537-38
306-11 400 binding and interaction
SUBJECT INDEX 609
sites on the cytoplasmic DNA binding domain (DBD), Dysoxylum binectariferum,
domain of NHE1, 536 3 329
calmodulin, 537 DNA code
phosphorylation, 535-37 flow of information from, E
Direct signaling by integrins, 109 Ebbinghaus, Hermann, 136
288-93 DNA methylation, 505-6 EC
direct activation of MAP and carcinogenesis, 506-9 See (—)-Epicatechin
kinase cascades by decreased availability of ECG
integrins, 289-91 methyl groups causing See (—)-Epicatechin gallate
focal adhesion kinase liver tumors in rodents, ECMs
(FAK), 288-89 508 See Extracellular matrix
integrin effects on Rho hypermethylation, 508-9 proteins
GTPases, 291-93 hypomethylation, 506-8 EcoCYC database, 126
integrin signaling to the maintenance of, 507 Ectromelia virus (EV), 483
cytoskeleton via Rho multiple factors Effectors of ERK, 148-52
GTPases, 292 controlling, 514 K* channel Kv4.2, 151-52
DISC possible inverse regulation of CREB
See Death inducing relationship between phosphorylation in the
signaling complex susceptibility to hippocampus, 150-51
Discovery carcinogenesis and transcription factor cAMP
of cdk inhibitors, 328-46 capacity of maintaining response element binding
of COX-2, 61-62 normal patterns of DNA protein, 148-49
Disease and inhibition, methylation, 509 Efficacy
482-88 Dobutamine (DOB), 359-60 in chemical space, relative
of chemokines, 482-88 DOI prevalence of, 366-67
other inhibitors, 488 See (+)-1-(2,5-Dimethoxy- defined, 349-50
other viral protein 4-iodopheny])-2- as a directional vector, 353
inhibitors, 483-84 amincepropane operational measurement
small-molecule antagonists Dopaminergic hypothesis, of, 367-70
of chemokine receptors, 166 quality of, 353-54
484-88 Dorsal horn at level of the EGC
viral chemokine primary afferent See (—)-Epigallocatechin
homologues, 482-83 synapse EGCG
Diverse databases DPDPE, 426 See (—)-Epigallocatechin
integrating data from, 123 Drosophila melanogaster, gallate
Diversity of 264, 307, 528 EGF
pharmacogenomic data, Drug and compound names, See Epidermal growth
118-20 121-22 factor
clinical data, 120 Drug efficacy at G Electrophysiological results
genomic data, 118-19 protein-coupled from typical LTP
molecular and cellular receptors, 349-79 experiment, 141
data, 119 Drug response Endogenous compounds
DMA using expression data to metabolism of, 3
See Dimethylamiloride assess phenotypes of, Endogenously expressed
DMBA 124-25 receptors
See 7,12-Dimethylbenz[a]- DuPont, 109 evidence of dimerization
anthracene Dysidea etheria, 226 for, 427-28
610 SUBJECT INDEX
Endothelium-derived relaxing (—)-Epigallocatechin gallate Excitatory postsynaptic
factor (EDRF), 593 (EGCG), 26-32, 38-46 potential (EPSP), 140
ENNG bioavailability of, 31 Expression data
See N-Ethyl-N’-nitro-N- Epigenetic basis for initiation using to assess phenotypes
nitrosoguanidine of carcinogenesis of drug response, 124-25
Ensembl browser, 118 possible, 504-5 Extended ternary complex
Ensemble theory in GPCR Epigenetic mechanisms (ETC) model
dynamics, 354-56 and carcinogenesis, 503-4 ofG protein activation,
Enterococci, 381 importance of, 503—5 351-53
Environmental insult during inheritance considered on a eXtensible Markup Language
development dual level, 503 (XML), 122
potential consequences of, initiation and cell Extracellular matrix (ECM)
185 proliferation in multistage proteins, 284
Environmentally induced carcinogenesis, 504 Extracellular-signal-regulated
birth defects, 181-208 possible basis for initiation kinase (ERK), 143
definitions of congenital of carcinogenesis, 504-5 biochemical information
anomalies, 183-88 possible key role of processing by, 152-54
developmental processes, increased gene expression as a biochemical
184-87 without mutation in information storage
gene environment carcinogenesis, 505 mechanism, 154
interaction concepts, Epithelial-mesenchymal as a biochemical switch,
188-92 interactions, 186 153
potential consequences of EPSP as a coincidence detector,
environmental insult See Excitatory 153-54
during development, 185 postsynaptic potential effectors of, 148-52
proposed molecular ERK electrophysiological results
mechanisms of known See Extracellular from typical LTP
teratogens, 193-99 signal-regulated kinase experiment, 141
Eotaxin, 90 Escherichia casseliflavus, 391 general attributes of
Epicatechin digallate, 26 E. coli, 387, 389, 392, 528 regulation, 143-44
(—)-Epicatechin (EC), 26-27, E. facaelis, 389, 392-93 Hebb’s postulate, 135-36
29-32, 41 E. flavescens, 391 hippocampal formation,
(—)-Epicatechin gallate E. gallinarum, 391-92 139
(ECG), 26-27, 29-32, Etanercept, 87 kinases in long-term
41, 4445 ETC potentiation, 142-43
Epidemiological studies See Extended ternary in long-term potentiation
relating aspirin intake to complex model (LTP), 138-43
reduced mortality from N-Ethyl-N’-nitro-N- in memory, 136-38
colon cancer, 60 nitrosoguanidine mitogen-activated protein
on tea and cancer, 41-42 (ENNG), 39 kinase cascade in
Epidermal growth factor Ethylisopropylamiloride memory, 135-63
(EGP), 38, 186, 287, 294 (EIPA), 530 in neurons, 146-48
Epigallocatechin digallates, EV regulation in neurons,
26 See Ectromelia virus 143-48
(—)-Epigallocatechin (EGC), Evolution of A-kinase regulation of, 143-48
26-27, 29-32, 41 anchoring proteins as a temporal integrator,
bioavailability of, 31 (AKAPs), 237-38 154